Visible Residual Disease Following Interval Debulking in Ovarian Cancer Is Associated With …
Visible Residual Disease Following Interval Debulking in Ovarian Cancer Is Associated With … Maintenance therapy with niraparib (Zejula) was associated with a significant reduction in the risk of disease progression in patients who had interval debulking surgery (IDS) and visible residual disease (VRD), according to results of a post hoc analysis of the phase 3 […]
Read More